I. Bence‐Bruckler

发表

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

R. Levy, M. Czuczman, A. Ho, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America

P. Bierman, I. Flinn, T. Shea, 2013 .

Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial

B. Leber, S. Kamel‐Reid, T. Stockley, 2021, British journal of haematology.

BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase

B. Leber, S. Kamel‐Reid, T. Stockley, 2021, British journal of haematology.

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

P. Bierman, I. Flinn, C. Flowers, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL

P. Laneuville, N. Berinstein, D. Stewart, 2023, European journal of haematology.

A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation

H. Atkins, L. Huebsch, S. Mcdiarmid, 1998, Bone Marrow Transplantation.

J. Goldberg, M. Jerkeman, M. Dreyling, 2017, Leukemia & lymphoma.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Nibedita Bandyopadhyay, Martin Dreyling, Mathias Witzens-Harig, 2016, The Lancet.

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

E. Kimby, N. Schmitz, H. Tilly, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC)

L. Huebsch, C. Bredeson, I. Bence-Bruckler, 1997, Bone Marrow Transplantation.

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

M. Czuczman, D. Maloney, J. Rosenberg, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

P. Stiff, K. Ruffner, B. Kahl, 2010 .

Effect of FCGR2A and FCGR3A variants on CLL outcome.

R. Yeh, O. Spleiss, D. Dornan, 2010, Blood.

Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL

L. Sehn, M. Oestergaard, M. Martelli, 2020 .

Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.

H. Atkins, D. Allan, L. Huebsch, 2016, JAMA neurology.

Lymphoproliferative lesions of the lacrimal gland: clinicopathological, immunohistochemical and molecular genetic analysis.

B. Burns, S. Gilberg, J. Farmer, 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.

H. Atkins, B. Hutton, D. Fergusson, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

D. Arnold, H. Atkins, A. Bar-Or, 2016, The Lancet.

Autologous blood and marrow transplantation in patients 60 years and older.

H. Atkins, L. Huebsch, C. Bredeson, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

B. Leber, S. Kamel‐Reid, J. Lipton, 2018, Blood.

Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.

L. Huebsch, I. Bence-Bruckler, R. Samant, 2010, International journal of radiation oncology, biology, physics.

A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia

H. Atkins, D. Allan, B. Zanke, 2015, Leukemia & lymphoma.

DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL

E. Kimby, N. Schmitz, S. Montoto, 2017 .

Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation

M. Crump, J. Nabholtz, A. Miller, 2000, Bone Marrow Transplantation.

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).

R. Advani, K. Savage, J. Radford, 2022, Clinical Lymphoma, Myeloma & Leukemia.